Edus H. Warren

10.2k total citations · 2 hit papers
149 papers, 7.0k citations indexed

About

Edus H. Warren is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Edus H. Warren has authored 149 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Immunology, 67 papers in Oncology and 56 papers in Hematology. Recurrent topics in Edus H. Warren's work include Hematopoietic Stem Cell Transplantation (46 papers), CAR-T cell therapy research (42 papers) and T-cell and B-cell Immunology (40 papers). Edus H. Warren is often cited by papers focused on Hematopoietic Stem Cell Transplantation (46 papers), CAR-T cell therapy research (42 papers) and T-cell and B-cell Immunology (40 papers). Edus H. Warren collaborates with scholars based in United States, South Africa and Japan. Edus H. Warren's co-authors include Stanley R. Riddell, Harlan Robins, Paulo Vidal Campregher, Philip D. Greenberg, M. Charles Liberman, Mary E.D. Flowers, Paul J. Martin, Cameron J. Turtle, Frederick R. Appelbaum and Christopher S. Carlson and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Edus H. Warren

139 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells

2009 780 citations Stanley R. Riddell, Edus H. Warren et al. Blood profile →
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

2011 453 citations Mary E.D. Flowers, Yoshihiro Inamoto et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edus H. Warren United States	43	3.7k	2.9k	2.3k	1.3k	746	149	7.0k
Warren D. Shlomchik United States	40	7.0k 1.9×	4.4k 1.5×	2.0k 0.9×	846 0.6×	423 0.6×	90	8.7k
Shunichi Kato Japan	43	2.2k 0.6×	3.0k 1.0×	956 0.4×	1.4k 1.1×	386 0.5×	171	6.2k
Kelli P. A. MacDonald Australia	47	5.0k 1.3×	1.8k 0.6×	1.1k 0.5×	1.4k 1.0×	254 0.3×	116	7.2k
Chaim Brautbar Israel	38	3.9k 1.0×	4.0k 1.4×	1.5k 0.7×	764 0.6×	877 1.2×	167	8.3k
Loredana Ruggeri Italy	35	7.5k 2.0×	5.3k 1.8×	3.1k 1.4×	552 0.4×	386 0.5×	89	9.3k
Els Goulmy Netherlands	50	7.1k 1.9×	3.6k 1.2×	1.7k 0.8×	1.5k 1.1×	897 1.2×	177	9.3k
Eddy Roosnek Switzerland	39	3.5k 0.9×	2.0k 0.7×	952 0.4×	729 0.5×	425 0.6×	120	5.9k
Marcelo Fernández-Viña United States	52	5.0k 1.4×	3.0k 1.0×	669 0.3×	818 0.6×	757 1.0×	235	8.3k
Kenneth I. Weinberg United States	51	4.1k 1.1×	2.1k 0.7×	2.2k 1.0×	3.9k 2.9×	1.7k 2.3×	180	10.8k
Michael Schmitt Germany	43	2.6k 0.7×	1.3k 0.4×	3.2k 1.4×	2.6k 1.9×	845 1.1×	273	7.1k

Countries citing papers authored by Edus H. Warren

Since Specialization

Citations

This map shows the geographic impact of Edus H. Warren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edus H. Warren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edus H. Warren more than expected).

Fields of papers citing papers by Edus H. Warren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edus H. Warren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edus H. Warren. The network helps show where Edus H. Warren may publish in the future.

Co-authorship network of co-authors of Edus H. Warren

This figure shows the co-authorship network connecting the top 25 collaborators of Edus H. Warren. A scholar is included among the top collaborators of Edus H. Warren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edus H. Warren. Edus H. Warren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Poh, Christina, Xueyan Chen, Jenna Voutsinas, et al.. (2025). Impact of immunophenotype on clinical disease characteristics and outcomes in T‐cell prolymphocytic leukaemia. British Journal of Haematology. 207(5). 2143–2146.

Poh, Christina, Jenna Voutsinas, Mazyar Shadman, et al.. (2025). Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas. Blood Advances. 9(15). 4037–4042. 1 indexed citations

Menon, Manoj, Henry Ddungu, Scott V. Adams, et al.. (2025). Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda. JCO Global Oncology. 11(11). e2400489–e2400489.

Poh, Christina, Victor A. Chow, Ryan C. Lynch, et al.. (2024). Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis. Transplantation and Cellular Therapy. 30(2). S33–S33.

Lynch, Ryan C., Ryan D. Cassaday, Stephen D. Smith, et al.. (2024). Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up. Blood. 144(Supplement 1). 3043–3043. 1 indexed citations

Huang, Jennifer J., Ryan Basom, Andrea Kalus, et al.. (2024). Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma. Blood. 144(Supplement 1). 7132–7132. 1 indexed citations

Warren, Edus H., et al.. (2021). RNA helicase, DDX3X, is actively recruited to sites of DNA damage in live cells. DNA repair. 103. 103137–103137. 18 indexed citations

Zeidan, Amer M., Hanna A. Knaus, Tara M. Robinson, et al.. (2018). A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clinical Cancer Research. 24(15). 3519–3527. 74 indexed citations

Coffey, David G., Christopher S. Carlson, Andrea Towlerton, et al.. (2017). High-throughput sequencing reveals novel features of immunoglobulin gene rearrangements in Burkitt lymphoma. Blood Advances. 1(16). 1261–1262. 1 indexed citations

10.

Coffey, David G., Christopher S. Carlson, Andrea Towlerton, et al.. (2017). High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis. Blood Advances. 1(9). 535–544. 17 indexed citations

11.

Martin, Paul J., David Levine, Barry E. Storer, et al.. (2016). Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. Blood. 129(6). 791–798. 76 indexed citations

12.

Inamoto, Yoshihiro, Paul J. Martin, Mary E.D. Flowers, et al.. (2016). Genetic risk factors for sclerotic graft-versus-host disease. Blood. 128(11). 1516–1524. 9 indexed citations

13.

Warren, Edus H., F. A. Matsen, & Jeffrey Chou. (2013). High-throughput sequencing of B- and T-lymphocyte antigen receptors in hematology. Blood. 122(1). 19–22. 19 indexed citations

14.

Flowers, Mary E.D., Yoshihiro Inamoto, Paul A. Carpenter, et al.. (2011). Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 117(11). 3214–3219. 453 indexed citations breakdown →

15.

Bleakley, Marie, Brith Otterud, Michael Hudecek, et al.. (2010). Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood. 115(23). 4923–4933. 79 indexed citations

16.

Eissa, Hesham, Ted Gooley, Mohamed L. Sorror, et al.. (2010). Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities. Biology of Blood and Marrow Transplantation. 17(6). 908–915. 81 indexed citations

17.

Nishida, Tetsuya, Michael Hudecek, Ana Kostić, et al.. (2009). Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia. Clinical Cancer Research. 15(14). 4759–4768. 31 indexed citations

18.

Tykodi, Scott S., Nobuharu Fujii, Nathalie Vigneron, et al.. (2008). C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients. Clinical Cancer Research. 14(16). 5260–5269. 43 indexed citations

19.

Warren, Edus H., Nathalie Vigneron, Marc A. Gavin, et al.. (2006). An Antigen Produced by Splicing of Noncontiguous Peptides in the Reverse Order. Science. 313(5792). 1444–1447. 160 indexed citations

20.

Warren, Edus H., Marc A. Gavin, Elizabeth Simpson, et al.. (2000). The Human UTY Gene Encodes a Novel HLA-B8-Restricted H-Y Antigen. The Journal of Immunology. 164(5). 2807–2814. 149 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact